论文部分内容阅读
目的：了解伊曲康唑间歇冲击疗法治疗甲真菌病的血清及甲中药物水平的变化，为该疗法提供药物动力学依据。方法１５例趾甲真菌病患者经伊曲康唑间歇冲击疗法治疗；于服药前、服药后每月取患者血清（共３月）并收集远端甲标本，将指甲和趾甲分开；以高效液相色谱（ＨＰＬＣ）测定伊曲康唑的含量。结果１每次冲击后４周，血清中均来测得伊曲康唑；２．甲组织中伊曲康唑水平较高，在２或３月时达到高峰；３．停药后，伊曲康唑仍能以较高的水平在甲中存在至６月后；同一时间点，指甲和趾甲中的药物水平无统计学差异（Ｐ＞０．０５）。结论伊曲康唑经口服吸收后从血液迅速向甲组织分布，停药后，以较高水平在甲组织中持续存在６月以上。
OBJECTIVE: To understand the changes of the serum and A drug levels in the treatment of onychomycosis by intermittent impact therapy with itraconazole to provide pharmacokinetic basis for this therapy. Methods Fifteen patients with toenail mycosis were treated with intermittent impact therapy with itraconazole. Before taking the medicine, the patients’ sera (3 months) were collected monthly and the distal specimens were collected to separate the nails and toenails. Determination of itraconazole by chromatography. Results 1 4 weeks after each impact, measured in serum are itraconazole; A group of high levels of itraconazole, peaked in February or March; 3. Itraconazole could still exist at a higher level in A to the end of June after stopping drug administration. There was no significant difference in the drug levels between nails and toenails at the same time point (P> 0.05). Conclusion Itraconazole is rapidly absorbed from the blood into the tissues of A after oral absorption. After withdrawal, itraconazole persists for more than 6 months in a tissue at a higher level.